GH
Guardant Health
GH · NASDAQ
$162.78 +1.36% (+$2.18)
1M -1.40%
Market Cap $21.8B
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$91.79
43.6% downside
Current Price
$162.78
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GH is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
0 /100
Expensive P/S 18.46x
P/FCF N/A
P/FFO N/A
Growth
100 /100
Growing Rev. growth 29.75%
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak FCF margin 20.35%
Op. margin 39.75%
Gross margin 65.01%
Quality
11 /100
Poor ROA 23.71%
Asset turnover 0.62x
ROIC 29.30%
Debt
43 /100
Moderate Int. coverage -93.37x
Current ratio 4.03x
Net debt/EBITDA N/A
Stability
67 /100
Stable Profitable years 0
EPS volatility 13.37%
Beta 1.59x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GH
Online
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Helmy Eltoukhy
Employees
2,498
Headquarters
Palo Alto
Upcoming events
28 OCT
Earnings
Upcoming earnings report